Journal
NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS
Volume 68, Issue -, Pages 387-409Publisher
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.neubiorev.2016.06.001
Keywords
Neuregulin 1; Schizophrenia; Psychosis; Excitatory neurotransmission; Inhibitory neurotransmission; Neuroimaging; Genotype; Transcript
Categories
Funding
- Cooperative Research Centre for Mental Health Top-up Scholarship
- One-in-Five Association Incorporated
- NHMRC [628386]
- Brain and Behavior Research Foundation (NARSAD) Distinguished Investigator Award
- National Health and Medical Research Council (NHMRC) [1045643, 1102012]
- Rebecca L. Cooper Medical Research Foundation Ltd.
- Schizophrenia Research Institute (from the NSW Ministry of Health)
- Schizophrenia Research Institute (from the Macquarie Group Foundation)
- University of New South Wales
- Neuroscience Research Australia
- National Health and Medical Research Council (Australia) [1021970]
- University of Melbourne Ronald Phillip Griffith Fellowship
- Brain and Behavior Research Foundation (NARSAD) Young Investigator Award [20526]
Ask authors/readers for more resources
Clinical and pre-clinical evidence has implicated neuregulin 1 (NRG1) as a critical component in the pathophysiology of schizophrenia. However, the arrival of the genome-wide association study (GWAS) era has yielded results that challenge the relevance of NRG1 in schizophrenia due to the absence of a genome-wide significant NRG1 variant associated with schizophrenia. To assess NRG1's relevance to schizophrenia in the GWAS era, we provide a targeted review of recent preclinical evidence on NRG1's role in regulating several aspects of excitatory/inhibitory neurotransmission and in turn schizophrenia risk. We also present a systematic review of the last decade of clinical research examining NRG1 in the context of schizophrenia. We include concise summaries of genotypic variation, gene-expression, protein expression, structural and functional neuroimaging as well as cognitive studies conducted during this time period. We conclude with recommendations for future clinical and preclinical work that we hope will help prioritize a strategy forward to further advance our understanding of the relationship between NRG1 and schizophrenia. (C) 2016 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available